EZH2 and breast carcinoma: Through the use of a breast cancer (MDA-MB-231) cell assay based on the re-expression of epigenetically silenced genes, we report the identification of hit compounds that phenocopy the effects of dual EZH2/EHMT2 pharmacological inhibition and dual SiRNA gene knockdown.